Pharmaceutical development of an oral tablet formulation containing a spray dried amorphous solid dispersion of docetaxel or paclitaxel

Emilia Sawicki*, Jos H Beijnen, Jan H M Schellens, Bastiaan Nuijen

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

Previously, it was shown in Phase I clinical trials that solubility-limited oral absorption of docetaxel and paclitaxel can be drastically improved with a freeze dried solid dispersion (fdSD). These formulations, however, are unfavorable for further clinical research because of limitations in amorphicity of SD and scalability of the production process. To resolve this, a spray drying method for an SD (spSD) containing docetaxel or paclitaxel and subsequently drug products were developed. Highest saturation solubility (Smax), precipitation onset time (Tprecip), amorphicity, purity, residual solvents, yield/efficiency and powder flow of spSDs were studied. Drug products were monitored for purity/content and dissolution during 24 months at +15-25°C. Docetaxel spSD Smax was equal to that of fdSD but Tprecip was 3 times longer. Paclitaxel spSD Smax was 30% increased but Tprecip was equal to fdSD. spSDs were fully amorphous, >99% pure, <5% residual solvents, mean batch yield was 100g and 84%. spSDs had poor powder flow characteristics, which could not be resolved by changing settings, but by using 75% lactose as diluent. The drug product was a tablet with docetaxel or paclitaxel spSD and was stable for at least 24 months. Spray drying is feasible for the production of SD of docetaxel or paclitaxel for upcoming clinical trials.

Original languageEnglish
Pages (from-to)765-773
Number of pages9
JournalInternational Journal of Pharmaceutics
Volume511
Issue number2
DOIs
Publication statusPublished - 25 Sept 2016

Keywords

  • Spray drying
  • Freeze drying
  • Lyophilization
  • Powder flow
  • Dissolution
  • Validation
  • Stability

Fingerprint

Dive into the research topics of 'Pharmaceutical development of an oral tablet formulation containing a spray dried amorphous solid dispersion of docetaxel or paclitaxel'. Together they form a unique fingerprint.

Cite this